[go: up one dir, main page]

WO2009069448A1 - Adjuvant for japanese b encephalitis vaccine, and japanese b encephalitis vaccine - Google Patents

Adjuvant for japanese b encephalitis vaccine, and japanese b encephalitis vaccine Download PDF

Info

Publication number
WO2009069448A1
WO2009069448A1 PCT/JP2008/070282 JP2008070282W WO2009069448A1 WO 2009069448 A1 WO2009069448 A1 WO 2009069448A1 JP 2008070282 W JP2008070282 W JP 2008070282W WO 2009069448 A1 WO2009069448 A1 WO 2009069448A1
Authority
WO
WIPO (PCT)
Prior art keywords
japanese
nucleotides
encephalitis vaccine
length
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/070282
Other languages
French (fr)
Japanese (ja)
Inventor
Tomokatsu Iwamura
Chikateru Nozaki
Kazuyoshi Kaminaka
Junichi Matsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Toray Industries Inc
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Toray Industries Inc filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Publication of WO2009069448A1 publication Critical patent/WO2009069448A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is a Japanese B encephalitis vaccine containing, as an adjuvant, a novel immunostimulating oligonucleotide having an enhanced interferon (IFN)-inducing activity and a reduced inflammatory cytokine-inducing activity. Also disclosed is an adjuvant for a Japanese B encephalitis vaccine, which comprises an oligonucleotide that is represented by the formula: 5'-(G)MPXCGYQ(G)N-3' [wherein C represents a cytosine residue; G represents a guanine residue; X and Y independently represent a nucleotide sequence that has a length of 0 to 10 nucleotides and does not contain contiguous four or more guanine residues (provided that the total length of X and Y is 6 to 20 nucleotides); XCGY represents a nucleotide sequence that has a length of 8 to 22 nucleotides and contains a palindrome sequence having a length of at least 8 nucleotides; P and Q independently represent a nucleotide residue other than a guanine residue; M represents an integer of 6 to 10; and N represents an integer of 0 to 3], and that has the total length of 16 to 37 nucleotides (provide that an oligonucleotide comprising the nucleotide sequence depicted in SEQ ID NO:5 in the Sequence Listing is excluded).
PCT/JP2008/070282 2007-11-28 2008-11-07 Adjuvant for japanese b encephalitis vaccine, and japanese b encephalitis vaccine Ceased WO2009069448A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-307932 2007-11-28
JP2007307932 2007-11-28

Publications (1)

Publication Number Publication Date
WO2009069448A1 true WO2009069448A1 (en) 2009-06-04

Family

ID=40678350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/070282 Ceased WO2009069448A1 (en) 2007-11-28 2008-11-07 Adjuvant for japanese b encephalitis vaccine, and japanese b encephalitis vaccine

Country Status (1)

Country Link
WO (1) WO2009069448A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9764031B2 (en) 2010-05-26 2017-09-19 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005083076A1 (en) * 2004-02-27 2005-09-09 Emori & Co., Ltd. Immune stimulant oligonucleotide inducing interferon alpha
WO2006035939A1 (en) * 2004-09-30 2006-04-06 Osaka University Immune stimulating oligonucleotide and use thereof in pharmaceutical
WO2006108358A1 (en) * 2005-04-13 2006-10-19 Changchun Huapu Biotechnology Co., Ltd. ANTIVIRAL USE OF ARTIFICIAL CpG-CONTAINING SINGLE-STRANDED OLIGODEOXYNUCLEOTIDES IN COMBINATION WITH RIBAVIRIN

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005083076A1 (en) * 2004-02-27 2005-09-09 Emori & Co., Ltd. Immune stimulant oligonucleotide inducing interferon alpha
WO2006035939A1 (en) * 2004-09-30 2006-04-06 Osaka University Immune stimulating oligonucleotide and use thereof in pharmaceutical
WO2006108358A1 (en) * 2005-04-13 2006-10-19 Changchun Huapu Biotechnology Co., Ltd. ANTIVIRAL USE OF ARTIFICIAL CpG-CONTAINING SINGLE-STRANDED OLIGODEOXYNUCLEOTIDES IN COMBINATION WITH RIBAVIRIN

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAMSTRUP, S. ET AL.: "Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides", VET MICROBIOL, vol. 78, no. 4, 2001, pages 353 - 362 *
YAMAMOTO, S. ET AL.: "Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity", J IMMUNOL, vol. 148, no. 12, 1992, pages 4072 - 4076 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9764031B2 (en) 2010-05-26 2017-09-19 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers

Similar Documents

Publication Publication Date Title
Unfried et al. Nucleotide sequence of the 5.8 S and 25S rRNA genes and of the internal transcribed spacers from Arabidopsis thaliana
WO2009061941A3 (en) Baseless nucleotide analogues and uses thereof
JP2010519915A5 (en)
RU2014117018A (en) APTAMER AGAINST NGF AND ITS APPLICATION
NZ594429A (en) Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
TW200745151A (en) Antiviral nucleosides
WO2009006478A3 (en) 6-disubstituted bicyclic nucleic acid analogs
RU2014130600A (en) ANTISONIC NUCLEIC ACIDS
WO2002069903A3 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0321306D0 (en) Modified polymerases for improved incorporation of nucleotide analogues
WO2003079757A3 (en) Hiv therapeutic
WO2010048549A3 (en) 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
NZ563845A (en) RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic
WO2005007875A3 (en) Enhanced promoters for synthesis of small hairpin rna
WO2007062160A3 (en) Methods and compositions for sequencing a nucleic acid
WO2009047610A8 (en) Immune stimulatory oligonucleotide analogs containing modified sugar moieties
RU2012100248A (en) APTAMER TO CHEMISTRY AND ITS APPLICATION
WO2007147067A3 (en) Methods and compositions for regulating cell cycle progression
MXPA01010392A (en) Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences.
WO2010040033A4 (en) Methods and compositions for modulating an immune response with immunogenic oligonucleotides
WO2009069447A1 (en) Adjuvant for influenza vaccine, and influenza vaccine
IL172015A0 (en) Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
AU2003291931A8 (en) Novel buffer formulations for isolating, purifying and recovering long-chain and short-chain nucleic acids
EP1803813A3 (en) An environmental stress-responsive promoter and an gene encoding environmental stress-responsive transcriptional factor
MXPA04004621A (en) Nucleosides preparation thereof and use as inhibitors of rna viral polymerases.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08853411

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08853411

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP